Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Ascites Volume (mL)
Study Overview
Brief Summary
To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.
Detailed Description
To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.
We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 1 Year to 80 Years (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All patients with CTPV.
Exclusion Criteria
- •Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.
Arms & Interventions
CTPV treated with Montelukast
Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
Intervention: Montelukast (Drug)
Outcomes
Primary Outcomes
Ascites Volume (mL)
Time Frame: 6 month
Ascites measured by CT scanning or ultrasound (If the patients had the history of ascites before)
Hydrothorax Volume (mL)
Time Frame: 6 month
Hydrothorax measured by CT scanning or ultrasound (If the patients had the history of hydrothorax before)
Secondary Outcomes
No secondary outcomes reported
Investigators
Zaibo Jiang
Department of Radiology, The Third Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University